Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2017-02-28 Declaration of Voting R…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Ändring av antalet aktier och röster i Oncopeptides AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement dated February 28, 2017, from Oncopeptides AB. The main subject is the 'Ändring av antalet aktier och röster' (Change in the number of shares and votes) due to new share issues ('nyemissioner') related to the listing on Nasdaq Stockholm. It explicitly states the new total number of shares and votes. This directly relates to changes in the company's capital structure and share count. The most fitting category is 'Share Issue/Capital Change' (SHA), as it details the result of a capital-raising event (new share issue) on the total share count. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a report publication announcement (RPA) as it contains the core information, not just a notice about an attachment.
2017-02-28 Swedish
Bolagets vd förvärvar aktier i Oncopeptides
Director's Dealing Classification · 1% confidence The document is a short announcement dated February 24, 2017, stating that the CEO of Oncopeptides AB purchased 45,000 shares of the company. This constitutes a report of personal share transactions by a company director/executive (insider trading). This directly matches the definition for Director's Dealing (DIRS). The document is short and is an announcement, not a comprehensive report, ruling out classifications like 10-K or IR.
2017-02-24 Swedish
Company's CEO Acquires Shares in Oncopeptides
Director's Dealing Classification · 1% confidence The document explicitly states that the company's CEO, Jakob Lindberg, acquired 45,000 shares. This action constitutes a personal share transaction by a company director/executive (insider trading/dealing). This directly matches the definition for Director's Dealing (DIRS). The document is short and is an announcement of this specific transaction, not a comprehensive report like a 10-K or IR.
2017-02-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.